IRIS
MARTORA, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.547
EU - Europa 2.114
NA - Nord America 1.080
SA - Sud America 513
AF - Africa 61
OC - Oceania 4
Totale 7.319
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 1.717
RU - Federazione Russa 1.075
US - Stati Uniti d'America 1.001
CN - Cina 992
DE - Germania 565
BR - Brasile 432
HK - Hong Kong 230
VN - Vietnam 202
IN - India 165
IT - Italia 161
KR - Corea 122
FI - Finlandia 92
GB - Regno Unito 41
NL - Olanda 41
AR - Argentina 40
MX - Messico 34
CA - Canada 27
BD - Bangladesh 26
FR - Francia 25
ES - Italia 21
UA - Ucraina 19
ZA - Sudafrica 19
AT - Austria 15
EC - Ecuador 15
ID - Indonesia 15
IE - Irlanda 11
PK - Pakistan 11
PL - Polonia 10
JP - Giappone 9
KE - Kenya 9
TR - Turchia 9
IQ - Iraq 8
MA - Marocco 8
CI - Costa d'Avorio 7
LT - Lituania 6
VE - Venezuela 6
CL - Cile 5
IL - Israele 5
PH - Filippine 5
RS - Serbia 5
SE - Svezia 5
DO - Repubblica Dominicana 4
JO - Giordania 4
OM - Oman 4
PY - Paraguay 4
UY - Uruguay 4
CO - Colombia 3
DZ - Algeria 3
EE - Estonia 3
KZ - Kazakistan 3
PA - Panama 3
RO - Romania 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AF - Afghanistan, Repubblica islamica di 2
AL - Albania 2
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
EG - Egitto 2
GH - Ghana 2
GN - Guinea 2
KH - Cambogia 2
MR - Mauritania 2
NI - Nicaragua 2
PE - Perù 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BE - Belgio 1
BN - Brunei Darussalam 1
BW - Botswana 1
CH - Svizzera 1
CV - Capo Verde 1
GM - Gambi 1
GR - Grecia 1
HT - Haiti 1
KG - Kirghizistan 1
KW - Kuwait 1
LC - Santa Lucia 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
MQ - Martinica 1
MY - Malesia 1
NC - Nuova Caledonia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
TN - Tunisia 1
TO - Tonga 1
TT - Trinidad e Tobago 1
Totale 7.317
Salva come PNG Salva come JPEG
Città #
Singapore 918
Hefei 614
Moscow 282
Hong Kong 228
Santa Clara 210
Beijing 158
Kochi 131
Munich 128
Seoul 122
Krefeld 113
Ashburn 97
Ho Chi Minh City 86
Los Angeles 55
Helsinki 53
Bad Bellingen 50
São Paulo 44
Hanoi 43
Redondo Beach 38
Naples 34
Dallas 29
Buffalo 25
Lappeenranta 20
The Dalles 20
New York 18
Chicago 17
Mexico City 17
Milan 16
Rome 15
Seattle 15
Boston 14
Brooklyn 13
Boardman 12
San Jose 12
Dublin 11
Nuremberg 11
Orem 11
Rio de Janeiro 11
Belo Horizonte 10
Turku 10
Poplar 9
Curitiba 8
Falkenstein 8
Nairobi 8
Atlanta 7
Campinas 7
Chennai 7
Da Nang 7
Denver 7
Kronberg 7
London 7
Montreal 7
Salvador 7
Warsaw 7
Xi'an 7
Amsterdam 6
Brasília 6
Florence 6
Frankfurt am Main 6
Guayaquil 6
Houston 6
Jyväskylä 6
Porto Alegre 6
Pune 6
Rochdale 6
Vienna 6
Ankara 5
Biên Hòa 5
Council Bluffs 5
Ha Long 5
Johannesburg 5
Mumbai 5
New Delhi 5
Phoenix 5
Ribeirão Preto 5
Salt Lake City 5
Santo André 5
Tokyo 5
Turin 5
Zhengzhou 5
Amman 4
Buenos Aires 4
Bắc Giang 4
Don Benito 4
Düsseldorf 4
Guarulhos 4
Haiphong 4
Lauterbourg 4
Manchester 4
Montevideo 4
Paris 4
Qingdao 4
Quito 4
Recife 4
San Juan 4
Santos 4
Stockholm 4
São José dos Pinhais 4
Tianjin 4
Toronto 4
Americana 3
Totale 4.040
Salva come PNG Salva come JPEG
Nome #
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 373
Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis 258
Comprehensive Molecular Analysis of Disease-Related Genes as First-Tier Test for Early Diagnosis, Classification, and Management of Patients Affected by Nonsyndromic Ichthyosis 127
Tattooing and hidradenitis suppurativa: stigmatization and camouflage 114
Comment on ‘Anogenital dermatology: challenges in the digital era’ 111
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256" 109
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 105
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review 104
Risk Factors for Psoriasis Flares: A Narrative Review 103
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 103
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 103
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 101
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection 101
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 98
Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting 98
Management of Psoriasis Patients with Serious Infectious Diseases 97
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 97
The use of ChatGPT in the dermatological field: a narrative review 97
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature 96
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 92
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review 92
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature 92
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation 92
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19 91
Comment on ‘Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine’ 89
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation 89
How Adalimumab Impacts Antibiotic Prescriptions in Patients Affected by Hidradenitis Suppurativa: A 1-Year Prospective Study and Retrospective Analysis 88
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 87
Comment on: “Clinical characteristics of patients with pityriasis rubra pilaris following SARS‐CoV‐2 vaccination” by Gambichler 87
Oral Minoxidil for Chemotherapy-Induced Alopecia 87
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? 86
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced 86
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities 86
Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study 86
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 85
Airborne allergic contact dermatitis "by proxy" due to budesonide 85
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 84
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 84
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 83
Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab" 83
Very low-calorie ketogenic diet (VLCKD) in the management of hidradenitis suppurativa (Acne Inversa): an effective and safe tool for improvement of the clinical severity of disease. Results of a pilot study 82
Lichen planus following Covid-19 vaccination: a narrative review 79
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation 79
Reply to 'Omalizumab for the management of refractory aquagenic pruritus' 79
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study 79
Climate change and the role of dermatologists: a call to action 78
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 78
Comment on ‘Permethrin-unresponsive scabies in London, UK: a wake-up call’ 78
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab 77
Dietary intervention in acne management: review of the literature and future prospective 76
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 75
Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al 75
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature 74
The Past, the Present and the Future of Teledermatology: A Narrative Review 74
Reply to Borgia et al. Comment on “Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J. Clin. Med. 2022, 11, 1511” 71
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Daungsupawong et al 71
Comment on 'Development of Chilblains Lesions During the COVID-19 Pandemic is Strongly Associated with Cold Weather: Retrospective Analysis of Patients from a Single Center in the United States' 68
Herpes Zoster and COVID-19 Vaccination: A Narrative Review 68
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation 68
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report 68
Effectiveness, Safety, and Long-Term Continuation Rate Analysis of Dupilumab Treatment in Adolescents with Atopic Dermatitis: A Single-Center Real-Life Retrospective Study 68
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study 68
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study 68
An update on the current and emerging pharmacotherapies for basal cell carcinomas 67
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review 65
ChatGPT and Dermatology: friends or foes? 63
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature 63
ChatGPT and dermatology 62
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis 62
Author Reply to “Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?” by Duff et al 61
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 61
Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa” 59
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter] 58
Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa” 57
Allergic contact dermatitis to petrolatum: An unknown for patch testing 53
Advancing Dermatology: Embracing the Power of Artificial Intelligence 53
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study 53
Comment on ‘Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination’ 51
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association 50
ChatGPT and Medical Writing in Dermatology: why should we keep writing? 49
Management of Advanced Invasive Melanoma: New Strategies 48
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments 47
Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study 46
Comment on “Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review” 45
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report 45
Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’ 45
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient 44
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 41
Comment on ‘Oral ivermectin to treat scabies: a comparison of two different regimens’ 36
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 34
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review 34
Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico II 27
Reply to 'Rifampicin and clindamycin for epidermal growth factor receptor inhibitor-related acneiform rash' 11
Hidradenitis suppurativa and bimekizumab: Looking to the future 10
Bimekizumab for Hidradenitis Suppurativa from Trials to Real Life: A Review of the Published Literature 1
Totale 7.431
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.913
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.913
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202383 0 0 0 0 0 10 11 17 3 16 17 9
2023/2024720 13 22 50 18 11 24 16 42 331 40 77 76
2024/20252.993 104 158 35 31 79 237 288 243 201 398 998 221
2025/20263.635 576 873 637 610 729 200 10 0 0 0 0 0
Totale 7.431